Thursday, 19 July 2018 - 6:41
  • it
  • de
  • en
  • fr

Lymphoma

Business of CAR-T gene therapies for lymphoma heats up

Excitement among Investors in the CAR-T business mounted and shares of the companies focusing on CAR-T reacted yesterday as it was announced that Kite/Gilead’s CAR-T therapy Yescarta significantly increases–by 15.4 months–life expectancy of patients with lymphoma. Gilead’ shares rose over…

European Commission approves MSD’s Keytruda for Hodgkin Lymphoma

MSD announced that the European Commission approved Keytruda (pembrolizumab) for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin, or who are transplant-ineligible. The approved…